| The pathogenesis and therapy of muscular dystrophies S Guiraud, A Aartsma-Rus, NM Vieira, KE Davies, GJB van Ommen, ... Annual review of genomics and human genetics 16 (1), 281-308, 2015 | 315 | 2015 |
| Pharmacological advances for treatment in Duchenne muscular dystrophy S Guiraud, KE Davies Current opinion in pharmacology 34, 36-48, 2017 | 182 | 2017 |
| Advances in genetic therapeutic strategies for Duchenne muscular dystrophy S Guiraud, H Chen, DT Burns, KE Davies Experimental physiology 100 (12), 1458-1467, 2015 | 99 | 2015 |
| Second-generation compound for the modulation of utrophin in the therapy of DMD S Guiraud, SE Squire, B Edwards, H Chen, DT Burns, N Shah, A Babbs, ... Human molecular genetics 24 (15), 4212-4224, 2015 | 97 | 2015 |
| The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy S Guiraud, D Roblin, DE Kay Expert Opinion on Orphan Drugs 6 (3), 179-192, 2018 | 45 | 2018 |
| Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD S Guiraud, B Edwards, SE Squire, L Moir, A Berg, A Babbs, N Ramadan, ... Human molecular genetics 28 (2), 307-319, 2019 | 41 | 2019 |
| The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy S Guiraud, B Edwards, A Babbs, SE Squire, A Berg, L Moir, MJ Wood, ... Human Molecular Genetics 28 (13), 2189-2200, 2019 | 39 | 2019 |
| Identification of serum protein biomarkers for utrophin based DMD therapy S Guiraud, B Edwards, SE Squire, A Babbs, N Shah, A Berg, H Chen, ... Scientific reports 7 (1), 43697, 2017 | 37 | 2017 |
| HANAC Col4a1 mutation in mice leads to skeletal muscle alterations due to a primary vascular defect S Guiraud, T Migeon, A Ferry, Z Chen, S Ouchelouche, MC Verpont, ... The American Journal of Pathology 187 (3), 505-516, 2017 | 33 | 2017 |
| Micro-utrophin improves cardiac and skeletal muscle function of severely affected D2/mdx mice TL Kennedy, S Guiraud, B Edwards, S Squire, L Moir, A Babbs, G Odom, ... Molecular Therapy-Methods & Clinical Development 11, 92-105, 2018 | 31 | 2018 |
| Regenerative biomarkers for Duchenne muscular dystrophy S Guiraud, KE Davies Neural regeneration research 14 (8), 1317-1320, 2019 | 28 | 2019 |
| Micro-dystrophin genes bring hope of an effective therapy for Duchenne muscular dystrophy KE Davies, S Guiraud Molecular Therapy 27 (3), 486-488, 2019 | 27 | 2019 |
| Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle TL Kennedy, L Moir, S Hemming, B Edwards, S Squire, K Davies, ... Skeletal muscle 7, 1-13, 2017 | 24 | 2017 |
| 2-Arylbenzo[d]oxazole Phosphinate Esters as Second-Generation Modulators of Utrophin for the Treatment of Duchenne Muscular Dystrophy A Babbs, A Berg, M Chatzopoulou, KE Davies, SG Davies, B Edwards, ... Journal of Medicinal Chemistry 63 (14), 7880-7891, 2020 | 22 | 2020 |
| Identification of decorin derived peptides with a zinc dependent anti-myostatin activity S Guiraud, L van Wittenberghe, C Georger, D Scherman, A Kichler Neuromuscular Disorders 22 (12), 1057-1068, 2012 | 22 | 2012 |
| The reverse block copolymer Pluronic 25R2 promotes DNA transfection of skeletal muscle S Guiraud, D Alimi‐Guez, L van Wittenberghe, D Scherman, A Kichler Macromolecular bioscience 11 (5), 590-594, 2011 | 19 | 2011 |
| Synthesis of SMT022357 enantiomers and in vivo evaluation in a Duchenne muscular dystrophy mouse model A Babbs, A Berg, M Chatzopoulou, KE Davies, SG Davies, B Edwards, ... Tetrahedron 76 (2), 130819, 2020 | 13 | 2020 |
| Discovery of small molecule utrophin modulators for the therapy of Duchenne muscular dystrophy G Wynne, A Vuorinen, E Emer, D Conole, M Chatzopoulou, S Davies, ... Neuromuscular Disorders 27, S189, 2017 | 1 | 2017 |
| CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments M Laurent, M Geoffroy, G Pavani, S Guiraud Cells 13 (10), 800, 2024 | | 2024 |
| Enhancing Utrophin Expression in Cell by Inducing Mutations Within Utrophin Regulatory Elements and Therapeutic Use Thereof M Amendola, S Guiraud US Patent App. 18/024,102, 2023 | | 2023 |
